Merck & Company Inc is trading at $114.95 (-3.18%) following mixed oncology news flow from the ASCO conference and a broader reset in investor expectations.
- The intraday selloff follows recent late-May strength, with investors appearing to take profits despite positive data regarding KEYTRUDA combinations.
- The decline is largely company-specific, as the broader market remains mixed to positive while Merck recalibrates after its recent rally.